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ABSTRACT 
Hypertrophic cardiomyopathy (HCM) is a common cardiovascular condition that is defined by 
unexplained left ventricular hypertrophy. A causative pathogenic variant can be detected via 
molecular testing in the majority of HCM cases. Pediatric HCM cases are typically predicted to be 
more severe than adult-onset cases and are more likely to be associated with a pathogenic variant. 
Barriers to genetic testing that have been established by prior studies include individual barriers 
such as unawareness and/or lack of knowledge regarding genetic services and institutional barriers 
including healthcare professionals’ lack of awareness and knowledge regarding genetic services. 
The purpose of the study was to better elucidate the barriers to genetic testing in pediatric HCM 
patients and their families at UPMC Children’s Hospital of Pittsburgh. 
Data was collected via an anonymous survey utilizing Qualtrics software. The survey was 
distributed through a recruitment letter and several reminder emails that contained survey links. 
Of the 12 respondents, 7 (58.3%) had pursued genetic testing for their child. Of the 5 participants 
whose children had not received genetic testing, 4 (80%) expressed interest in pursuing it but had 
not for reasons including insurance denial, uncertainty regarding how to pursue it, and more 
pressing health concerns for their child. Lastly, this study identified deficits in respondents’ 
understanding of GINA. 
 v 
This study identified several important findings that have public health significance and 
can be utilized to develop a plan to address barriers to genetic testing within this patient population. 
To reduce the chance the genetic testing gets denied by insurance, healthcare institutions should 
make every effort to ensure patients receive an intake, evaluation, education, and consent by a 
genetic counselor. Additionally, genetic counselors can typically offer alternative finance options 
by working directly with the lab, to decrease the chance that cost is a barrier. Methods to address 
this and additional concerns regarding education and awareness within this population can be 
directed by the newly formed Cardiovascular Genetics Clinic at UPMC Children’s Hospital of 
Pittsburgh. 
 vi 
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1.0 INTRODUCTION 
Hypertrophic cardiomyopathy (HCM) is a common cardiovascular condition that is 
estimated to affect approximately 1 in 500 adults (Maron et al., 1995). HCM is characterized by 
thickening of the left wall of the heart and can involve symptoms including chest pain, dyspnea, 
syncope/presyncope, seizures, heart palpitations, dizziness, fatigue, or malaise (Lynge et al., 
2016). Often, sudden cardiac death is the first clinical presentation of HCM without any preceding 
cardiac symptoms (Maron et al., 1982). In about 60% of HCM cases, a causative pathogenic 
variant can be detected via molecular testing (Gersh et al., 2011). HCM is also a relatively common 
childhood cardiac condition, with an estimated incidence of 0.47/100,000 children (Lipshultz et 
al., 2003). Pediatric HCM is associated with increased risk for cardiac arrest (Marian, 1995), 
increased severity, and increased likelihood of detecting a pathogenic variant associated with the 
condition (Gómez et al., 2016). Despite the valuable information that genetic testing can provide 
for children and families affected with HCM, genetic testing is still not yet a standard of care for 
pediatric HCM patients. Furthermore, many of these families do not receive genetic testing. 
Barriers to genetic testing that have been elucidated in other studies across different genetic 
counseling settings include inadequate insurance coverage, unawareness, low perceived 
susceptibility, anxiety and distress, financial concerns, limited interest, and provider failure to refer 
or recommend genetic testing (Anderson et al., 2012; Delikurt et al., 2014). Additionally, one study 
that looked at adult HCM patients specifically found that barriers to genetic testing included 
distress regarding genetic test results as a reason for not pursuing genetic services (Khouzam et 
al., 2015). 
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The purpose of this study is to explore what barriers to genetic testing exist in families of 
pediatric HCM patients. For this study, an anonymous survey was developed utilizing Qualtrics 
software through a University of Pittsburgh license and distributed via a recruitment letter and 
reminder emails to the parents of pediatric HCM patients who have been followed by the 
Department of Cardiology at UPMC Children’s Hospital of Pittsburgh. Inclusion criteria for this 
study included patients with a clinical diagnosis of non-syndromic HCM. Data were analyzed 
using descriptive statistics and included information from parents who pursued genetic testing for 
their child with HCM as well as parents who did not pursue genetic testing for their child with 
HCM. 
The results of this study have the potential to impact the standard of care for pediatric HCM 
patients and their families. First, this study can help determine the barriers to genetic testing within 
this population. This will allow clinicians, including cardiologists and genetic counselors, to 
address specific issues when they meet with these families to improve accessibility and awareness 
of genetic testing. Additionally, this study also has the potential to elucidate information regarding 
attitudes and understanding regarding what genetic testing and their child’s test result means for 
their family. While this study analyzes responses from a small sample in a specific geographic 
location, this survey can be applied to a larger patient population to determine if there are any 
statistically significant differences between families who have and have not pursued genetic testing 
in the measures that are assessed within this survey, including events surrounding diagnosis, family 
history, perceived risks and benefits of testing, and attitudes and beliefs towards genetic testing. 
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1.1 SPECIFIC AIMS 
Specific Aim 1: Survey the parents and/or guardians of pediatric patients with HCM who have 
been seen by pediatric cardiology at UPMC Children’s Hospital of Pittsburgh and received a 
clinical diagnosis of HCM. This sample will include families who have not received genetic testing 
for HCM as well as a comparison group of families who did pursue genetic testing. Surveying will 
be performed by utilizing and electronically distributing a survey instrument that will be obtained 
and adapted from Khouzam et al. (2015) with permission. 
Specific Aim 2: Analyze the survey data to elicit the reasons parents and/or guardians do not 
pursue genetic testing for their children. 
Specific Aim 3: Identify barriers so that strategies to reduce these barriers can be incorporated into 
the newly formed Cardiovascular Genetics Clinic, a collaborative effort between genetic 
counselors in the Division of Medical Genetics and physicians in Cardiology to increase the 
awareness and accessibility of genetics services to pediatric cardiology patients and their families 
at UPMC Children’s Hospital of Pittsburgh.        
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2.0 LITERATURE REVIEW 
2.1 HYPERTROPHIC CARDIOMYOPATHY 
Hypertrophic cardiomyopathy (HCM) is a common cardiovascular condition that is 
defined by unexplained left ventricular hypertrophy. The thickening of the left wall of the heart 
impairs the heart’s function and efficiency in pumping blood and can potentially block blood flow 
out of the left ventricle. Resulting clinical manifestations may include syncope, shortness of breath, 
and/or sudden cardiac death; however, most individuals with HCM are asymptomatic. Other 
pathologic features that are associated with HCM include asymmetric left ventricular hypertrophy 
that widely varies with respect to extent and location, reduced left ventricular cavity dimensions, 
hyperdynamic systolic dysfunction, papillary muscle abnormalities, irregularities of the mitral 
valve, and atypical diastolic function with atrial enlargement (Klues et al., 1995). HCM can be 
sporadic or familial and is clinically and genetically heterogeneous, even within families. This 
literature review will primarily discuss familial HCM and examine the distinction between 
pediatric and adult HCM, as pediatric patients with HCM and their families are the focus of this 
study. 
2.1.1  Clinical Features 
The majority of individuals with hypertrophic cardiomyopathy are asymptomatic (Maron 
et al., 2000; Spirito et al., 1989). The most common symptoms of HCM can include chest pain, 
dyspnea, syncope/presyncope, and seizures; additional clinical manifestations of HCM can also 
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include heart palpitations, dizziness, fatigue, or malaise (Lynge et al., 2016). In a subset of 
individuals, sudden cardiac death is the first clinical presentation of HCM without any preceding 
cardiac symptoms (Maron et al., 1982). In about 25% of HCM cases, left ventricular outflow tract 
obstruction (LVOTO) is present (Maron et al., 2003b). This finding in the context of an HCM 
diagnosis has been associated with more rapid deterioration and an increased risk for sudden 
cardiac death. Furthermore, LVOTO is typically managed and treated differently than non-
obstructive hypertrophic cardiomyopathy (NOHCM), which will be further discussed in section 
2.1.6. 
A study that was conducted between 1970 and 1999 followed 225 patients for yearly 
intervals in order to better understand the clinical course and outcomes of HCM and evaluate risk 
factors that can precede sudden cardiac death. The findings of this study revealed that syncope was 
the only risk factor significantly associated with an increased risk of sudden cardiac death. 
Additionally, patients with a significant LVOTO typically resulted in decreased functional status 
at follow-up, while NOHCM patients tended to have a more prolonged and stable clinical course 
(Kofflard et al., 2003). Another study aimed to compare the LVOTO and NOHCM through 
analysis of the electrical activity, heart imaging studies, and clinical findings of 44 patients. Results 
of this study indicated that there was a greater incidence of myocardial infarction, increased 
interventricular septum measurement, and reduced telesystolic diameter of the left ventricle in the 
LVOTO compared to the NOHCM group. Conversely, there was increased supraventricular 
arrhythmia and reduced left ventricular hypertrophy in the NOHCM group. The study’s 
researchers also found a higher overall prevalence of NOHCM versus LVOTO; there were no age 
or sex differences between the LVOTO and NOHCM groups. Additionally, in both types of 
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cardiomyopathy, improvement with treatment was more likely to be sustained with calcium 
antagonists than beta-blockers (Almenar et al., 1996).  
In terms of prognosis, historical estimates of HCM mortality rates in adults ranged from 2-
4% per year, which were primarily established by early retrospective studies (Kofflard et al., 1993). 
As management and treatment for HCM has improved over time and the research studies have 
become more accurate, mortality estimates for individuals with HCM have decreased across all 
ages. Multiple large cohort studies have been conducted recently that have established a mortality 
rate of 0.5% in children, adolescents, young adults, adults, and advanced age HCM patients (Maron 
et al., 2015; Maron et al., 2013; Maron et al., 2016). 
2.1.1.1 Pediatric Clinical Features 
Hypertrophic cardiomyopathy has been traditionally considered an adult-onset condition; 
HCM most commonly emerges during adolescence or adulthood and the average age of diagnosis 
is approximately 39 years old, according to the Hypertrophic Cardiomyopathy Association 
database (“When Does Hypertrophic Cardiomyopathy Develop?” n.d.). However, HCM is also a 
relatively common childhood cardiac condition that can manifest differently than in adulthood. In 
fact, research has indicated that pediatric HCM cases are associated with increased severity and an 
increased likelihood to be associated with a pathogenic variant than adult-onset HCM cases (Bales 
et al., 2016).  
It has been historically estimated that up to 40% of children with pediatric 
cardiomyopathies, including HCM, progressed to death or required a heart transplant within 5 
years of their initial diagnosis (Kindel et al., 2012). This can be contrasted with the results of an 
adult HCM study that analyzed a sample of 1259 HCM patients from three cohorts. This study 
found that only 3.5% of HCM patients progressed to end-stage disease with systolic dysfunction, 
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LV dilation, and/or LV hypertrophy; the mean age of the patients in this study was 40 years (range: 
3 to 63 years) at initial evaluation (Harris et al., 2006). Furthermore, prior studies that evaluated 
the progression of HCM in adults estimated only up to 15% of the individuals with the condition 
progressed to end stage (Maron and Spirito, 1998; Spirito et al., 1987). 
More recent pediatric research that directly disputes the finding that almost half of children 
with HCM experience significant heart disease progression. Colan et al., 2007 aimed to analyze 
the epidemiology and outcomes of pediatric HCM and was conducted utilizing the Pediatric 
Cardiomyopathy Registry (PCMR), which is a research registry that has been funded by National 
Heart Lung and Blood Institute and has followed more than 3500 North American children with 
cardiomyopathy (Wilkinson et al., 2010). The sample for this study consisted of 855 children, who 
were all under the age of 18. The results of the study indicated that diagnosis of idiopathic HCM 
carries a worse prognosis in infancy, but if an infant survives past 1 year old, then the survival rate 
is equivalent to survival rate at any age of diagnosis (Colan et al., 2007).  
There are also historical misestimations regarding the mortality rate of pediatric HCM. 
Previous pediatric studies completed in the United States reported an annual mortality rate of up 
to 6% (Arghami et al., 2017). However, a study analyzed PCMR data that stratified specific risk 
factors in 1085 children with HCM and compared mortality and heart transplantation rates between 
groups. The results of this study indicate that children with multiple risk factors, including an 
underlying metabolic condition, mixed hypertrophic and dilated cardiomyopathy, or restrictive 
cardiomyopathy, have an increased risk for sudden cardiac death or requiring a heart 
transplantation (Lipshultz et al., 2013). These varied estimates in pediatric studies indicate that 
further research is required to elucidate a more accurate approximation of pediatric HCM mortality 
rates; certain subgroups may have a significantly increased risk for mortality, which is distorting 
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the true prognosis for a typical diagnosis of pediatric HCM (Lipshultz et al., 2013). However, 
whether or not the mortality rate is overestimated, affected children are at higher risk for sudden 
cardiac death than affected adults (Marian, 1995). In consideration of the more recent research on 
pediatric HCM in conjunction with the advent of more effective surgical interventions, the 
prognosis for pediatric HCM is better than previously reported. 
2.1.2  Prevalence 
Historically, the estimated prevalence of hypertrophic cardiomyopathy in adults is about 1 
in 500. This estimate was based on a study that looked at echocardiographic data of 4,111 subjects 
ages 23-35 in the Coronary Artery Risk Development in (Young) Adults (CARDIA) sample that 
took place between 1987 and 1988 (Maron et al., 1995). However, with the rise of genetic testing, 
detection of pathogenic variants in the general population, and identification of more at-risk and 
affected individuals, recent data indicate that the estimate for HCM prevalence is as high as about 
1 in 200 (Semsarian et al., 2015).  
2.1.3  Diagnosis 
Familial HCM can be diagnosed clinically and by molecular testing. However, HCM often 
has multiple cardiac and/or genetic differential diagnoses that should be considered during 
evaluation. Heart conditions that can mimic the features of familial HCM include acquired left 
ventricular hypertrophy, cardiac amyloidosis, and PRKAG2-associated disorders; HCM in these 
conditions may be transient or secondary to an underlying accumulation of amyloid protein or 
glycogen, respectively (Cirino and Ho, 2008).  
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There are also possible underlying genetic, metabolic, and neuromuscular conditions that 
are associated with HCM. These are typically distinguished from familial, idiopathic HCM by the 
presence of additional symptoms, which may be harder to discern in a pediatric population. Some 
genetic conditions that should be ruled out in the context of HCM include Fabry disease, Danon 
disease, Pompe disease, mitochondrial disease, Noonan syndrome, and Friedrich ataxia (Cirino 
and Ho, 2008). One study that looked at 855 children affected with HCM found that 25.2% had an 
underlying metabolic, neuromuscular, or malformation condition; the remainder were diagnosed 
with idiopathic HCM (Colan et al., 2007). This study underlines the importance of evaluating 
HCM patients for potential differential diagnoses, especially in a pediatric setting.  
2.1.3.1 Clinical Testing 
HCM is typically clinically diagnosed utilizing non-invasive cardiac imaging technologies, 
including an echocardiogram or cardiac magnetic resonance imaging. Clinical diagnostic criteria 
for HCM state that heart wall thickness must be increased to 1.5 cm or greater in adults (Maron et 
al., 2003a). In children, a diagnosis can be made for an increased heart wall thickness equivalent 
to that in an adult relative to body surface area (Gersh et al., 2011). 
2.1.3.2 Molecular Testing 
Molecular testing can provide a genetic diagnosis of HCM for individuals who may or may 
not clinically present with the condition. The genes that are most frequently associated with 
familial HCM are MYH7 and MYBPC3, which each account for about 40% of pathogenic variants 
that are associated with HCM (Hershberger et al., 2018; Cirino and Ho, 2008). Additional HCM-
associated core genes, as established by the Heart Failure Society of America in collaboration with 
the American College of Medical Genetics and Genomics, include TNNT2, TNNC1, TNNI3, 
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TPM1, MYL2, MYL3, ACTC1, ACTN2, CSRP3, PLN, TTR, PRKAG2, LAMP2, and GLA 
(Hershberger et al 2018).  
Pre-conception and prenatal testing for HCM is becoming increasingly more common, as 
genetic testing for HCM is becoming more widespread and additional genetic causes of HCM are 
being identified. Pre-implantation genetic diagnosis (PGD) for inherited cardiac diseases has been 
researched and successfully completed in multiple couples. One specific study described 18 PGD 
cycles undergone by patients who had a genetic predisposition for a cardiac disease; three patients 
in the study carried a pathogenic variant associated with HCM. The outcomes of this study 
included the births of seven children that did not carry a disease-causing or disease-predisposing 
pathogenic variant. However, no successful births occurred for the patients with an HCM-
associated pathogenic variant. This study did not explore the motivations of the families who 
underwent PGD testing for familial HCM. However, this paper alludes to the fact that while certain 
inherited cardiac disease may be milder, the initial presentation could potentially be premature 
death which warrants offering the option of PGD to those families (Kuliev et al., 2012). 
2.1.4  Molecular Genetics 
HCM is considered the most common inherited cardiac disease (Maron et al., 2014). In 
about 60% of HCM cases, a causative pathogenic variant can be detected via molecular testing 
(Gersh et al., 2011). The majority of genetic changes interfere with the function of the sarcomere 
(Ho and Seidman, 2006). The sarcomere is the basic unit of muscle structure; sarcomeres are 
contractile regions in the myofilament structure composed of actin and myosin. In addition to 
HCM, sarcomere dysfunction has also been implicated in heart failure and other familial heart 
conditions such as dilated cardiomyopathy (DCM) (Hamdani et al., 2008; Lakdawala et al., 2010). 
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There is significant genetic heterogeneity present in HCM. In fact, most pathogenic 
variants that are associated with familial HCM are specific to an individual family and are unlikely 
to be detected in unrelated individuals (Ho, 2013). An OMIM search of ‘hypertrophic 
cardiomyopathy’ yields 1,035 results (“OMIM Entry Search,” 2018). A ClinVar search of 
‘hypertrophic cardiomyopathy’ yields 6383 results (“ClinVar Entry Search,” 2018b). It is 
important to note that HCM is a feature of several genetic conditions, which was discussed in 
section 2.1.3; thus, these conditions are included in the search results in addition to familial, 
idiopathic HCM. When ‘familial hypertrophic cardiomyopathy’ was searched in ClinVar, this 
yielded 3326 results. Of these variants, only 523 are classified as ‘pathogenic,’ while 2,001 are 
classified as ‘uncertain significance’ (“ClinVar Entry Search,” 2018a). The large number of 
variants that have been identified and suggested to potentially be associated with HCM 
underscores the clinical utility of larger-scale genetic testing, including panel and exome testing; 
this will further detect and clarify variants associated with HCM, which will ultimately lead to 
cascade screening and identification of at-risk family members.  
There are also potential drawbacks of larger-scale genetic testing within the context of 
HCM, given there are almost four times the number of variants of uncertain significance suggested 
to be associated with HCM compared to known pathogenic variants. One study conducted by 
Gómez et al. (2016) found that an estimated 11% of patients with HCM who receive genetic testing 
are found to have rare variants unique to his or her family. Furthermore, it is unlikely that all of 
these variants are pathogenic and may be benign genetic changes unrelated to an HCM diagnosis. 
However, given the rarity of these variants and the fact that many will unlikely be found in other 
families, laboratories’ abilities to gather more information regarding these rare genetic changes are 
limited. This study also indicated that the likelihood of finding a pathogenic variant is increased 
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when patients have severe early-onset HCM and/or a related family history (Gómez et al., 2016). 
Given the potential for uncertainty, especially in HCM patients with a milder phenotype, advanced 
age of onset, and no family history, informed consent is imperative for families interested in 
pursuing genetic evaluation. 
2.1.4.1 Factors Associated with Familial HCM 
One study was conducted to analyze the clinical predictors of genetic testing outcomes in 
HCM. This research took place over a 10-year period; 265 unrelated probands were studied. Of 
these individuals, 138 probands (52%) tested positive for at least one pathogenic variant causative 
of HCM. The results of this study also indicated via multivariate analysis that female sex, increased 
left ventricular wall thickness, a family history of HCM and/or sudden cardiac death were the 
clinical factors associated with the greatest chance of identifying a pathogenic variant (Ingles et 
al., 2013).  
While family history is a valuable clinical tool in increasing the detection rate of pathogenic 
variants, isolated HCM cases may still have an underlying genetic basis. Another study provided 
genetic testing to 57 individuals with either an HCM or DCM diagnosis. Of the individuals tested, 
70% received positive genetic testing for a pathogenic variant. Of the probands with a positive 
result, almost half (40%) reported no family history of cardiomyopathy at their initial evaluation 
(Miller et al., 2013). As previously discussed, the first symptom of HCM is often sudden cardiac 
death. While a “negative” family history may indicate that close relatives of the proband were not 
formally diagnosed with HCM, there may be clinical indications including non-specific symptoms 
or causes of death that may suggest relatives were affected but undiagnosed. Thus, genetic testing 
is important to offer to all HCM patients, even in the context of a “negative” family history.  
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2.1.4.2 Genotype-Phenotype Correlation 
Familial HCM has a number of genotype-phenotype correlations, of which a select few 
will be highlighted in this section. The aforementioned study by Ingles et al. (2013) also analyzed 
genotype-phenotype correlation in carriers of pathogenic variants associated with HCM. 
Individuals in this study who carried a pathogenic variant in TNNT2 received an earlier diagnosis, 
while carriers of pathogenic variants in the TNNI3 gene had an increased likelihood of an out-of-
hospital cardiac arrest or sudden cardiac death. Additionally, individuals in this study who carried 
a pathogenic variant in MYH7 presented clinically and were diagnosed at significantly younger 
ages than carriers of an MYBPC3 pathogenic variant. In addition, a research study conducted by 
Viswanathan et al. (2017) showed that the HCM phenotype that arose from pathogenic variants in 
MYBPC3 is indistinguishable from an MYH7 HCM phenotype. 
Genotype-phenotype correlation has also been researched with respect to carriers of 
multiple genetic changes in genes that are associated with HCM. About 6% of patients with HCM 
have been reported to carry 2 or more sarcomere variants. Carriers of multiple pathogenic variants 
were more likely to have an out-of-hospital cardiac arrest or sudden cardiac death than carriers of 
a single pathogenic variants (Ingles et al., 2013). Other characteristics of individuals who carry 
multiple pathogenic variants causative of HCM also can include more significant left ventricular 
hypertrophy, earlier age at diagnosis, and treatment with invasive surgical intervention (Ingles et 
al., 2005). Additionally, some pathogenic variants that are causative of HCM have also been 
Currently, there is limited clinical utility in using genotypic information to predict risks and guide 
management. However, further research on genotype-phenotype correlation in familial HCM 
could lead to the development of risk-stratification algorithms that can predict clinical outcomes 
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to guide management based on the number of pathogenic variants a patient has, in which genes 
they are located, and the specific pathogenic variant(s) identified. 
2.1.5  Inheritance 
Familial HCM is inherited in an autosomal dominant manner. If an individual is identified 
to have a pathogenic variant that is causative of HCM, there is a 50% risk that he or she will pass 
the pathogenic variant to each future child. The de novo mutation rate in patients with HCM is 
estimated to be about 30% (Konno et al., 2010).  
HCM, like other inherited cardiac disease, has variable expressivity and incomplete, age-
dependent penetrance. A study conducted by Jensen et al. (2013) that examined 90 probands and 
361 relatives who underwent clinical screening and/or genetic testing and found that only 6% of 
at-risk relatives of probands were identified to have HCM during childhood or early adulthood, 
suggesting a low penetrance rate.  
2.1.6  Management 
There are several management and treatment options for both children and adults who have 
been diagnosed with HCM. The recommendations of these options depend on severity of disease, 
age-of-onset, and family history. Typically, these management guidelines and treatment options 
are available for both children and adults, unless indicated otherwise. While there is no cure for 
HCM, there are ways to manage and treat symptoms of the condition as well as reduce the risk for 
sudden cardiac death.  
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2.1.6.1 Surveillance 
Individuals who are diagnosed with HCM are recommended to follow-up for clinical, 
echocardiographic, and electrocardiographic evaluation every 12-18 months following initial 
diagnosis (Maron et al., 2003a). With respect to the management of family members, current 
guidelines recommend that all first-degree relatives of individuals with HCM are clinically 
evaluated via 12-lead ECG and annually imaged for children beginning around age 10-12 years 
until age 18-21 years, and every 2-5 years in adults (Elliott et al., 2014). Lifestyle changes, 
pharmaceutical therapy, and prophylactic surgical intervention are not indicated for at-risk 
individuals until cardiac evaluations indicate a clinical diagnosis of HCM. 
2.1.6.2 Lifestyle Changes 
Lifestyle changes in individuals with HCM are typically the first management 
recommendation made for individuals with HCM, even before pharmaceutical therapy, in the 
context of an asymptomatic patient with a milder form of disease (Michels et al., 2017). The most 
common lifestyle change for individuals with HCM is limitation of physical activity. It is 
recommended that individuals with HCM do not play competitive sports of any kind. Any high-
intensity exercise or competitive physical activity that may involve impact puts an individual with 
HCM at higher risk for sudden cardiac death. However, low-impact, noncompetitive physical 
activity is encouraged for individuals with HCM. This may include some low-intensity weight 
lifting, recreational golf, or some light cardio (e.g., walking or running) (Elliott et al., 2014). 
2.1.6.3 Pharmaceutical Therapy 
Pharmaceutical management historically has been the first-line treatment option for 
patients with HCM. Prior to the introduction of more invasive preventative measures of sudden 
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cardiac death, pharmaceutical therapy was historically utilized to prevent sudden cardiac death in 
patients with HCM. However, it has been more recently established that medications are not 
effective in preventing sudden cardiac death (Melacini et al., 2007). 
While pharmacological treatments do not prevent sudden cardiac death, research has 
shown that medications can alleviate symptoms and improve the clinical course of HCM. One 
study that looked at both LVOTO and NOHCM found that calcium-antagonists were more likely 
than β-blockers to demonstrate an improved, prolonged clinical course in both groups (Almenar et 
al., 1996). The recommended progression of drug therapy in individuals with OCHM is to treat 
initially with ß-blockers; if those are ineffective and/or contraindicated, disopyramide and 
verapamil are considered second-line drug therapy options (Elliott et al., 2014). 
2.1.6.4 Surgical Intervention 
Surgical intervention is another recommended management approach for HCM, typically 
for individuals for whom medications have been attempted, individuals with severe symptoms, 
and/or individuals with LVOTO. In fact, the therapeutic gold standard for individuals with 
LVOTO and severe symptoms is a surgical myectomy, also known as a septal myectomy (Sorajja 
et al., 2009). This was established by a study that explored the long-term survival of individuals 
with HCM with LVOTO who received a surgical myectomy. This study’s sample consisted of 
1,337 HCM patients who were followed for an average of 6 years. Researchers compared total and 
HCM-related deaths between three subgroups: HCM patients with LVOTO who received a 
surgical myectomy, HCM patients with LVOTO who did not receive a surgical myectomy, and 
HCM patients without obstruction. The results of the study indicated that the survival rates in 
HCM patients with LVOTO who received surgical myectomy are comparable to age- and gender-
matched unaffected individuals in the general population as well as HCM patients without 
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obstruction. Additionally, HCM patients with LVOTO who received surgical myectomy had 
significantly higher survival rates when compared to HCM patients with LVOTO who did not 
receive surgical myectomy (Ommen et al., 2005). This study highlights the significantly improved 
outcomes for severely affected individuals that pursue this surgical option. To explore this surgical 
approach for other HCM populations, another study aimed to determine whether or not 
prophylactic surgical myectomy would be an appropriate treatment option for individuals without 
LVOTO. The results of this study indicated that mildly symptomatic or asymptomatic patients had 
only a slightly increased mortality rate over the general population and thus would likely not 
benefit from this treatment option (Sorajja et al., 2009). An alternative to this procedure is septal 
alcohol ablation, which has similar outcomes in functional status improvement and comparable 
procedural mortality risks when compared to surgical myectomy However, septal alcohol ablation 
carries an increased risk for AV block (Elliott et al., 2014). 
Another means of treatment for LVOTO is internal cardioverter defibrillator (ICD) 
implantation. Consideration of ICD implantation is recommended for patients who are considered 
moderate and high risk for sudden cardiac death (Elliott et al., 2014). This may be based on cardiac 
imaging, history of a documented abnormal heart rhythm, and/or family history of sudden cardiac 
death. ICD has been established as a highly effective treatment option in preventing sudden cardiac 
death. A study followed 16 HCM patients, all of whom were successfully screened, for a median 
17.5 months after they had ICDs placed. During this follow-up period, no appropriate shocks were 
required or administered in this cohort. However, one inappropriate shock was received by one 
individual during the follow-up period. No sudden cardiac deaths were noted (Weinstock et al., 
2016). 
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2.1.7  Genetic Screening Guidelines 
Current recommendations for screening in patients and families with HCM include genetic 
testing beginning with an affected family member, cascade screening for family members of 
individuals who have received a pathogenic or likely pathogenic genetic test result, and 
consideration of genetic testing for evaluation of HCM in infants (Hershberger et al., 2018). 
A recent study looked at the impact of genetic testing in probands and cascade screening 
in relatives. The study population consisted of 777 relatives of 209 unrelated probands, who had 
been evaluated for HCM between 1985 and 2016. A pathogenic variant that explained their HCM 
was found in 72% of these probands, and 80% of the total relatives pursued genetic testing. Almost 
half (43%) of the relatives tested positive for the known familial pathogenic variant. Another 
significant result of this study was that 46% of the relatives in the study were discharged from 
clinical follow-up based on their negative genetic test result (van Velzen et al., 2018). This study 
findings highlight the importance of genetic screening in conjunction with clinical evaluation in 
identifying family members of probands at-risk for HCM, as well as the value of genetic testing to 
prevent unnecessary clinical screening in family members who are not at risk. 
2.1.8  Impact of Genetic Evaluation  
Traditionally, individuals with HCM have been evaluated, diagnosed, and managed 
clinically. Today, research has established that HCM is an inherited condition that often has an 
underlying genetic basis. Both clinical and genetic evaluations of HCM can provide more detailed 
information regarding severity, management, inheritance, and prognosis than just clinical and/or 
genetic evaluation alone (Ho, 2010).  
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It has been proposed that incorporating genetic testing into the management of families 
with HCM creates a more cost-effective approach model than traditional clinical follow-up of at-
risk family members. As previously discussed, traditional surveillance recommendations for first-
degree relatives of an individual with HCM include regular cardiac screening and evaluation. 
Conversely, when a proband receives genetic testing and tests positive for a pathogenic variant 
causative for HCM, cascade screening of other family members can occur. This has the potential 
to identify family members who do not carry the known familial variant causative of the HCM in 
the family and who will no longer need regular cardiac evaluations and follow-up. Additionally, 
multiple studies have established genetic testing as a more cost-effective model in the evaluation 
of HCM patients and their family members when compared to traditional clinical management and 
screening methods (Ingles et al., 2012; Wordsworth et al., 2010). A study conducted by Ingles et 
al. (2012) aimed to analyze the cost difference via probabilistic mathematical modeling between 
incorporating genetic testing into management of Australian families with HCM compared to 
clinical follow-up without genetic testing. This study found that the proposed genetic testing 
strategy resulted in increases in quality-adjusted life years and life-years gained as well as resulted 
in a projected decrease in cost of proband testing; thus, this model would be highly cost-effective. 
The benefits of genetic testing in the diagnosis and management of HCM introduces the question 
of why some families with HCM do not pursue genetic services and/or genetic testing. 
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2.2 BARRIERS TO GENETIC SERVICES 
2.2.1  Definition 
Barriers to genetic services can be defined as the actual or perceived motivations that result 
in individuals with a genetic risk choosing (either knowingly or unknowingly) not to pursue 
genetic testing. Barriers that have been elucidated in previous studies include inadequate insurance 
coverage, unawareness, low perceived susceptibility, anxiety and distress, financial concerns, 
limited interest, and provider failure to refer or recommend genetic testing.  
The majority of research on the barriers to genetic services and testing was conducted 
within cancer genetic services. However, this research is informative for other genetic counseling 
settings, especially prior to the study of barriers within these settings. One study offered genetic 
counseling services to 97 women who were between the ages of 30 and 60 years with a family 
history of breast cancer. This study was unique because researchers offered free genetic counseling 
sessions, which removed cost as a potential barrier to genetic services. Fifty of the women accepted 
the offer of genetic counseling. Factors associated with individuals who were more likely to 
undergo genetic testing included increased perceived susceptibility to breast cancer and carrying 
a BRCA1 or BRCA2 pathogenic variant, as well as a higher education level. Of the 47 women who 
did not pursue genetic counseling, disinterest, not wanting to discuss breast cancer, not having 
enough time, experiencing unrelated health problems, and low perceived susceptibility to breast 
cancer were reasons to decline the service reported by 26 participants (Culver et al., 2001). 
Similarly, another study that looked at a population of women who were diagnosed with breast 
cancer before age 50 from 2006-2007 found that the most common reasons that were cited by 
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women who did not pursue genetic testing were lack of provider recommendation/referral and 
concerns regarding insurance coverage (Anderson et al., 2012).  
Delikurt et al. (2014) conducted a systematic review that analyzed the barriers to patient 
referral to genetic services based on the findings of nine articles. This paper differentiated the most 
frequently reported factors that are associated with underutilization of genetic services into two 
categories: barriers related to individuals and barriers related to healthcare professionals. 
Individual barriers included unawareness and/or lack of knowledge regarding personal risk, family 
member risk, and genetic services. Barriers related to healthcare professionals included lack of 
awareness and knowledge regarding patient risk factors and genetic conditions and services, not 
obtaining a complete family history, not properly coordinating or providing referral, or lack of 
genetics workforce. This systematic review identified findings delineated in the two 
aforementioned studies, which all indicate that the barriers to genetic testing primarily lie within 
the awareness and knowledge of the patient and their healthcare provider. 
2.2.2  Pediatric Genetic Services 
Barriers to genetic testing in pediatric populations have been analyzed for various 
conditions, as genetic testing for pediatric conditions has become more prevalent.  For example, 
one study looked at the reasons that genetic testing was not pursued as frequently as expected in 
families with children who have an autism diagnosis. The researchers received 155 unique survey 
responses for this study and found that the major factors that affected families pursuing genetic 
testing included failure of provider to recommend testing, parental unawareness, parental 
disinterest, and inadequate insurance coverage. It was also found that families who pursued genetic 
testing were more likely to ask for a referral to genetics and/or more likely to have primary care 
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providers who suggested genetic services. Additional factors that were associated with families 
who did not pursue genetic testing in this study included low parental anxiety and distress (Vande 
Wydeven et al., 2012). 
Another study that looked at the barriers to genetic testing in the context of pediatrics 
specifically aimed to analyze the barriers to genetic testing in a population of children with public 
insurance, or Medicaid. This study was unique because researchers analyzed survey responses that 
were elicited from 302 healthcare providers (from a population of 1982 healthcare providers), 
which was primarily composed of neurologists (82%) but also represented resident physicians, 
nurses, and nurse practitioners. Barriers that were cited from the healthcare provider prospective 
included cost, provider understanding and expertise, commercial laboratories, healthcare 
institution, specific insurance company and coverage, and patient attitudes. These reasons were 
further explored through a qualitative research component of the study. For example, cost 
subthemes cited by respondents included that testing is too expensive, and cost outweighs benefit 
for their patients. Providers also discussed that they were limited in their ability to offer genetic 
testing, as they did not fully understand the value of genetic testing, did not know how to complete 
the paperwork required, and did not have enough time in appointments to fully consent patients. 
In terms of commercial laboratories, healthcare providers cited that labs offer too many options, 
and providers did not know the most appropriate test to order for their patient. In regard to 
healthcare institutions, providers noted that insufficient staffing as well as stricter institutional 
policies (e.g., requiring patients to see a genetic counselor to move forward with testing) are also 
significant barriers to genetic testing. Respondents discussed that insurance companies have 
denied testing for patients and that families cannot afford the out-of-pocket cost for testing. Lastly, 
patient attitudes, specifically regarding privacy and fears of misuse of their genetic information, 
 23 
was another specific barrier cited by respondents (Kutscher et al., 2017). This research is important 
because it elicited healthcare providers’ perceptions of barriers to genetic testing, which provides 
more information underlying the reasons that healthcare providers themselves either do not or 
cannot provide genetic services and/or genetic testing. 
Barriers to pediatric genetic testing concerns that were emphasized throughout both parent 
and provider studies include financial considerations, such as parental financial concerns as well 
as concerns regarding insurance coverage, insurance providers, and billing issues (Vande 
Wydeven et al., 2012; Kutscher et al., 2017). Another factor that was emphasized in regard to 
barriers in pediatric genetic services is the child’s primary care provider’s and/or other specialty 
doctor’s knowledge and comfort of coordinating, referring, and ordering genetic services and 
genetic testing, particularly in clinics without genetic professionals (Vande Wydeven et al., 2012; 
Kutscher et al., 2017). These specific barriers are of particular relevance to specialty clinics that 
provide services for children with conditions that may have a genetic etiology, but do not have 
access to genetic professionals (e.g., neurology and cardiology). 
2.2.3  Cardiovascular Genetic Services 
Barriers to genetic testing in patients seeking genetic counseling for specific cardiovascular 
conditions have been identified by several studies. A study that investigated barriers to genetic 
testing in 306 patients with HCM and their family members found that individuals who had genetic 
testing were more likely to have seen a genetic professional, have a family history of HCM, and 
have a known familial pathogenic variant that is associated with HCM. Additionally, this study 
revealed that individuals with HCM and their families cited distress regarding genetic test results 
as a reason for not pursuing genetic services (Khouzam et al., 2015).  
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Because insurance coverage has been cited as a barrier to genetic testing in both general 
and cardiovascular genetics services specifically, research has been performed that analyzed the 
issues in accessibility and cost associated with cardiovascular genetic testing. This research 
indicates that there are multiple challenges within the US healthcare system, from insurance 
policies to commercial laboratory billing practices to healthcare provider knowledge. For example, 
insurance policies often exclude cardiovascular genetic testing from coverage, citing it as 
“experimental,” or stating it will not change an affected patient’s medical management. 
Additionally, guidelines for cardiovascular genetic testing are updated infrequently and are not 
specific, compared to cancer genetic screening guidelines, which may be another factor 
contributing to insurance companies’ decision not to cover testing. Lastly, clinician unawareness 
of commercial laboratory policies, which typically include payment plans and cost reductions 
whenever genetic testing is billed directly to the laboratory rather than the institution, could result 
in a large out-of-pocket cost for the patient and even legal liability for the healthcare provider 
(Spoonamore and Johnson, 2016).  
2.2.3.1 Psychosocial Factors 
Psychosocial factors associated with inherited cardiovascular diseases may contribute to 
barriers to genetic testing in this specific population. A study conducted by Hidayatallah et al. 
(2014) aimed to elucidate psychosocial factors specific to families with inherited cardiovascular 
conditions by interviewing 50 participants from 32 families who were either being followed for a 
cardiogenetic condition, were parents of children who had predispositions to arrhythmias and 
sudden cardiac death or were families of children who passed away from explained causes. The 
theme that was most frequently cited by participants was guilt (N=33). These participants also 
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expressed recurring ideas including bereavement (e.g., numbness, disbelief), reactive anxiety (e.g., 
guilt, fear), and positive outcomes (e.g., closure, gratitude) regarding their experiences.  
A systematic review outlined the recommendations for genetic counseling and testing for 
individuals with inherited cardiovascular disease by summarizing the potential positive and 
negative psychological impacts and modifiers for affected adults, unaffected at-risk adults, and 
unaffected at-risk children. This review is important because it addresses psychosocial issues 
unique to children, which is a perspective that is lacking in other research studies on this topic. 
Potential negative impacts of genetic testing in children at-risk for an inherited cardiovascular 
condition include frustration regarding stigmatization (genotype positive), altered self-esteem, 
distress over the testing process and outcome, modification of identity regarding professional 
aspirations and hobbies, survivor guilt (genotype negative), and the removal of some autonomy by 
the parent pursuing the testing.  Potential positive impacts of genetic testing for children include 
the elimination of uncertainty, empowerment, permitting an adjustment period to a diagnosis 
(genotype positive), and providing relief (genotype negative). Modifiers associated with more 
positive impacts are positive parental attitudes, higher socioeconomic status and education level, 
reduced disease severity, good prognosis, and low rate of cardiac death in the family history (Aatre 
and Day, 2011). 
Another qualitative study has identified additional psychosocial and ethical implications 
that may act as barriers to genetic testing. Ormondroyd et al. (2013) interviewed 22 individuals 
who have a clinical and/or genetic diagnosis of HCM or Long QT Syndrome (LQTS) and found 
that probands often failed to communicate with at-risk family members, since they did not 
understand the value of genetic testing. Furthermore, asymptomatic individuals viewed their risk 
as low, even when they were genotype positive. These potential psychosocial barriers may lead to 
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the increased unawareness regarding genetic testing in cardiovascular conditions among family 
members of affected individuals as well the general population. Challenges in communication or 
understanding can occur at many stages throughout the genetic testing process. For example, there 
may have been a failure of the healthcare provider to accurately relay the impact of the genetic test 
result to the patient. Additionally, patient misunderstanding could still occur even if the healthcare 
provider provided an accurate explanation, which could stem from reasons including low health 
literacy, limited knowledge regarding genetics, or even denial over a clinical and/or genetic 
diagnosis. This study also explored parents’ reasons for pursuing or not pursuing genetic testing 
for their children. Parents cited not wanting to cause their child worry or negatively impacting their 
life through the stigmatization of a genetic diagnosis and potential limitation of physical activity 
as reasons for not pursuing genetic testing. Interestingly, this study also looked at quality-of-life 
scores for children diagnosed with inherited cardiovascular condition and found that they were not 
significantly different than their peers without a diagnosis.  Overall, unawareness and 
misunderstanding of the utility of genetic testing as well as parental attitudes in the case of pediatric 
genetic testing may serve as potential explanations regarding why individuals who are at-risk with 
a family history are not pursuing genetic services.  
The distinct barriers to cardiovascular genetic testing including unique psychosocial 
concerns associated with carrying a genetic change that can cause sudden cardiac death, inaccurate 
perception of risk due to the asymptomatic nature of most cardiovascular conditions, and the 
exclusion of coverage by insurance companies for cardiovascular genetic testing demonstrates the 
need for further research to be performed regarding the access and awareness of cardiovascular 
genetic testing for patients and their families. 
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3.0 MANUSCRIPT 
3.1 BACKGROUND 
Hypertrophic cardiomyopathy (HCM) is a common cardiovascular condition that is 
characterized by thickening of the left wall of the heart. HCM commonly involves symptoms such 
as chest pain, dyspnea, syncope/presyncope, and seizures; additional clinical manifestations of 
HCM can include heart palpitations, dizziness, fatigue, or malaise (Lynge et al., 2016). Often, 
sudden cardiac death is the first presenting feature of HCM without any preceding cardiac 
symptoms (Maron et al., 1982). HCM can be diagnosed clinically utilizing non-invasive cardiac 
imaging technologies, including an echocardiogram or cardiac magnetic resonance imaging. 
Individuals diagnosed with HCM are recommended to have clinical, echocardiographic, and 
electrocardiographic evaluation every 12-18 months following an initial diagnosis (Maron et al., 
2003a). Lifestyle changes, pharmaceutical therapy, and prophylactic surgical intervention are all 
potential management and treatment options for individuals with HCM, depending on the 
symptoms a patient is exhibiting as well as disease severity and progression. 
It is estimated that HCM affects approximately 1 in 500 adults (Maron et al., 1995) and is 
the most common inherited cardiac disease (Maron et al., 2014).  In addition to traditional clinical 
diagnostic testing and follow-up, HCM can also be diagnosed through genetic testing. In fact, in 
about 60% of HCM cases, a causative pathogenic variant can be detected via molecular testing 
(Gersh et al., 2011). The genes that are most frequently associated with familial HCM are MYH7 
and MYBPC3, which each account for about 40% of pathogenic variants that are associated with 
HCM (Hershberger et al., 2018; Cirino and Ho, 2008). Additional HCM-associated core genes, as 
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established by the Heart Failure Society of America in collaboration with the American College 
of Medical Genetics and Genomics, include TNNT2, TNNC1, TNNI3, TPM1, MYL2, MYL3, 
ACTC1, ACTN2, CSRP3, PLN, TTR, PRKAG2, LAMP2, and GLA (Hershberger et al., 2018). The 
majority of genetic changes interfere with the function of the sarcomere (Ho and Seidman, 2006). 
Genetic diagnosis has the potential to determine an underlying hereditary predisposition that can 
explain a patient’s clinical HCM diagnosis, rule out potential syndromic causes of HCM, and 
identify at-risk individuals (e.g., unaffected relatives of an individual with HCM) who do not have 
a clinical presentation of HCM but have a high risk to develop the condition based on a positive 
genetic test result. Current recommendations for screening in patients and families with HCM 
include genetic testing beginning with an affected family member, cascade screening for family 
members of individuals who have received a pathogenic or likely pathogenic genetic test result, 
and consideration of genetic testing for evaluation of HCM in at-risk infants (Hershberger et al., 
2018). 
3.1.1  Impact of Genetic Testing 
Finding a pathogenic variant that is causative of HCM in an affected proband allows for 
at-risk family members to be evaluated and have appropriate management and follow-up, 
depending on their genetic status. In fact, research has shown that genetic testing in unaffected 
relatives has the potential to discharge nearly 50% of individuals being regularly followed due to 
a family history of HCM based on a negative genetic test result (van Velzen et al., 2018). Thus, 
genetic testing not only alleviates the burden of unnecessary clinical follow-up of unaffected 
family members, but several studies have shown that genetic screening for family members of an 
affected proband found to have a pathogenic variant is more cost-effective for institutions and 
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insurance companies compared to traditional clinical screening and follow-up (Ingles et al., 2012; 
Wordsworth et al., 2010). While clear benefits of genetic testing and cascade screening exist for 
an inherited cardiac condition, a risk of genetic testing for HCM is uncertain results and negative 
psychological impacts of testing. At this time, there are almost four times the number of variants 
of uncertain significance suggested to be associated with HCM compared to known pathogenic 
variants (ClinVar, 2018). However, certain clinical factors are associated with a greater chance of 
identifying a pathogenic variant, including increased severity of disease, female sex, increased left 
ventricular wall thickness, a family history of HCM and/or sudden cardiac death (Ingles et al., 
2013; Gómez et al., 2016). In addition to the potential for uncertainty, research has identified 
psychosocial issues such as low-perceived risk, which can impact a patient’s ability to fully 
understand their genetic test result and accurately communicate that information to at-risk family 
members (Ormondroyd et al., 2013). Additional psychosocial concerns associated with a positive 
genetic test result, especially in asymptomatic patients, include stigmatization related to a genetic 
diagnosis, the potential impact of a positive genetic test result on self-image, and the 
mental/emotional toll of physical activity restriction. (Aatre and Day, 2011). The fact that many 
families with HCM do not receive genetic testing for this condition, especially in the context of 
documented benefits and risks, suggests that further research into the barriers for families with 
HCM to receive genetic services is warranted. 
3.1.2  Barriers to Genetic Testing 
Research has identified barriers for patients pursuing genetic testing in several types of 
genetic counseling practice settings. The bulk of this research is focused in cancer genetic 
counseling, but these results have the potential to be informative for other genetic counseling 
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specialties. These studies established patient-specific barriers including unawareness and/or lack 
of knowledge regarding personal risk, family member risk, and genetic services. Additionally, 
barriers related to healthcare professionals were also corroborated by multiple studies, including 
lack of awareness and knowledge regarding patient risk factors and genetic conditions and 
services, not obtaining a complete family history, not properly coordinating or providing referral, 
or lack of genetics workforce (Culver et al., 2001; Anderson et al., 2012; Delikurt et al., 2014). 
Findings from studies examining barriers in both pediatric and cardiovascular genetics practices 
were consistent with this prior research as well. Barriers to pediatric genetic testing concerns that 
were emphasized throughout both parent and provider studies include financial considerations, 
such as parental financial concerns as well as concerns regarding insurance coverage, insurance 
providers, and billing issues. Furthermore, families who pursued genetic testing were more likely 
to ask for a referral to genetics and/or more likely to have primary care providers who suggested 
genetic services. Additional factors that were associated with families who did not pursue genetic 
testing included low parental anxiety and distress (Vande Wydeven et al., 2012). Other barriers 
identified in pediatric genetic services is the child’s primary care provider’s and/or other specialty 
doctor’s knowledge and comfort of coordinating, referring, and ordering genetic services and 
genetic testing. Barriers that were cited from the healthcare provider prospective included cost, 
provider understanding and expertise, commercial laboratories, healthcare institution, specific 
insurance company and coverage, and patient attitudes (Kutscher et al., 2017). Research has been 
performed that identified and analyzed the issues in accessibility and cost associated with 
cardiovascular genetic testing. One finding was the exclusion by insurance policies of 
cardiovascular genetic testing from coverage, citing it as “experimental,” or stating it will not 
change an affected patient’s medical management. Additionally, guidelines for cardiovascular 
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genetic testing are updated infrequently and are not specific, compared to cancer genetic screening 
guidelines, which may be another factor contributing to insurance companies’ decision not to cover 
testing. Lastly, clinician unawareness of commercial laboratory policies, which typically include 
payment plans and cost reductions whenever genetic testing is billed directly to the laboratory 
rather than the institution, may result in a large out-of-pocket cost for the patient and even legal 
liability for the healthcare provider (Spoonamore and Johnson, 2016).  
Research investigating facilitators and barriers to genetic testing in an HCM population, 
specifically, has been limited. Facilitators to genetic testing in adult HCM patients include meeting 
with a genetics professional, having a family history of HCM, and having a known familial 
pathogenic variant that is associated with HCM. Barriers to genetic testing in this population 
include distress regarding genetic test results as a reason for not pursuing genetic services 
(Khouzam et al., 2015). There is a paucity of research examining the barriers that exist for pediatric 
patients with HCM. Pediatric HCM cases are associated with increased severity and an increased 
likelihood to be associated with a pathogenic variant when compared to adult-onset HCM cases 
(Bales et al., 2016). Therefore, the clinical utility of testing pediatric patients may be increased due 
to a higher yield and a lower risk for uncertainty. Despite the benefits and potential positive impact 
that exists for genetic testing in this population, many families do not pursue genetic testing or 
obtain genetic services, including genetic counseling. This disparity merits additional research to 
explore the barriers that prevent these patients and their families from obtaining genetic services 
and genetic testing.   
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3.1.3  Study Goals 
This study aimed to gather data on the barriers to uptake of genetic services for pediatric 
HCM patients by surveying parents of affected children who pursued genetic testing and parents 
of affected children who did not pursue genetic testing. To our knowledge, this is the first study 
that looks specifically at barriers to genetic testing in a pediatric HCM population and can provide 
important preliminary evidence for the reasons that some families have genetic testing while others 
do not. Demographic information, risk factors, reasons for genetic testing decisions, and attitudes 
towards genetic testing were elicited and assessed to better understand the motivators and barriers 
for genetic testing for these families. The results of the study have the potential to impact the way 
providers address the topic of genetic testing in a clinical setting with their patients. Additionally, 
this research may impact the collaboration between cardiology and genetic providers, especially 
in a pediatric setting. This research was conducted during the development of the Cardiovascular 
Genetics Clinic at UPMC Children’s Hospital of Pittsburgh, which is multidisciplinary approach 
to patient care; similar models have been adopted by pediatric institutions throughout the United 
States. This type of clinic often involves a genetic counselor who performs important tasks 
including taking a detailed family history, educating families about the option genetic testing, 
having a comprehensive discussion regarding its risks and benefits, and offering information 
regarding insurance coverage or alternative financial options for genetic testing. While these 
factors are instrumental to the genetic counseling pre-test process, a traditional cardiology clinic 
may not have the proper time or resources for a thorough discussion. The ultimate goal of the study 
is to explore possible gaps in patient care and education in regards to genetic testing, which has 
the potential to be addressed by a multidisciplinary model like the Cardiovascular Genetics Clinic, 
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in order to reduce barriers that may prevent pediatric patients and their families from pursuing 
genetic testing for HCM. 
3.2 METHODS 
3.2.1  Participants 
The target population for this survey included parents or guardians of HCM patients who 
have been seen by the Division of Cardiology at UPMC Children’s Hospital of Pittsburgh. The 
Division of Cardiology has been maintaining a Microsoft Excel spreadsheet of its patients since 
January 2017; participants were recruited using this data. Prior to gaining access to this patient 
information, the study was reviewed and approved by the University of Pittsburgh Institutional 
Review Board (IRB) committee (Appendix A). Researchers were granted access to this 
spreadsheet upon IRB approval. For each patient, information that was found within this document 
included name, date of birth, medical record number, diagnosis information, sex, and 
race/ethnicity. A medical record review was performed utilizing this information to verify 
diagnoses and record contact information for each patient and their family. Physical mailing 
addresses, phone numbers, and email addresses (for families who disclosed their email addresses 
in their medical record) were recorded during the medical record review. The genetic testing status 
of each patient was also recorded. 
There were 113 patients identified with a diagnosis of HCM. The following criteria for the 
exclusion of patients included: a diagnosis of HCM secondary to another condition (e.g., genetic 
diagnosis like Fabry, mitochondrial disease, etc.), the family had moved, the patient had been 
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discharged from care by the Department of Cardiology at Children’s Hospital, positive genetic 
diagnosis but failure to meet clinical diagnostic criteria for HCM, or other complex social 
situations. For example, one individual was omitted from the study when medical record review 
indicated that this individual had lost both parents to heart conditions. Another individual omitted 
from the study had severe intellectual disability and now was living in an adult group home. Age 
was an important consideration regarding the study population, as the focus of the study was 
genetic testing in pediatric HCM patients. However, if the patient had been seen recently and it 
appeared that the patient lived with their parents, then a recruitment letter was sent to their 
household, even if the patient was 18 years or older at the time of study initiation.  
After exclusion criteria was applied to this population, 70 patients which comprised 63 
households were eligible for the study. Since some individuals were siblings of one another, 
participants were instructed to fill out the survey in reference to their most recently diagnosed 
child. 
3.2.2  Survey Development 
The survey that was created for this study was adapted from Khouzam et al. (2015) 
(Appendix B) with permission. It was reviewed and edited by two genetic counselors, a 
cardiologist, and a statistician during its development. The survey was published as an online 
questionnaire utilizing Qualtrics software, which was accessed through a University of Pittsburgh 
license.  
The survey is comprised of five sections: introduction and consent, general diagnosis and 
family history, genetic evaluation, attitudes towards genetic testing, and demographic information. 
The introduction and consent section contained information about the survey, potential risks and 
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benefits, and contact information of the primary researcher. To continue with the survey, 
participants had to consent to the survey in this section. The next section of the survey was general 
diagnosis and family history, in which the participant provided information regarding their child’s 
age and diagnosis, family history of HCM and/or sudden cardiac death, and personal perception 
of risk and surveillance history. The genetic evaluation section of the survey queried about whether 
or not the participant’s child had genetic testing. For participants who said yes, they were asked 
follow-up questions regarding who their child’s healthcare providers were, the result of the genetic 
test, and the ways that genetic testing was valuable or not for their child. For participants whose 
child did not have genetic testing, follow-up questions included whether or not they were interested 
in testing, the reasons that they have not pursued genetic testing, and what information they would 
like to know before pursuing genetic testing for their child. The next section of the survey, attitudes 
towards genetic testing, elicited participants’ perceptions regarding main risks and benefits of 
genetic testing. Additionally, participants were asked to respond to statements formatted in a 5-
point Likert-style scale (strongly agree, somewhat agree, neither agree nor disagree, somewhat 
disagree, and strongly disagree) about various attitudes, beliefs, and facts regarding genetic testing. 
The final section asked participants about demographic information regarding their child and their 
family. Questions elicited information about the child’s age, race, and sex; additional questions 
inquired about classification of the family’s home community, distance from UPMC Children’s 
Hospital of Pittsburgh, and insurance coverage information. 
Skip logic was utilized throughout the survey, so participants would only be shown 
questions that were relevant to answers they previously provided. The survey was made available 
via an anonymous web link.  
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3.2.3  Survey Recruitment and Distribution 
The survey was initially distributed via a recruitment letter mailed in October 2018 
(Appendix C). The letter was signed by Dr. Mousumi Moulik, who is a member of the cardiology 
clinical team. This letter briefly explained the project and its purpose and included an anonymous 
link for the survey, as well as the primary researcher’s contact information. Of the 63 households 
to which the survey was distributed, 40 families had email addresses listed in the electronic medical 
record system. Following the distribution of the recruitment letters, reminder emails were sent to 
these 40 households; the first reminders were sent in November 2018 and second reminder emails 
were sent in December 2018 (Appendix D). The survey remained open for four months, from 
October 2018 to February 2019.  
3.2.4  Data Analysis 
Descriptive statistics, including means, ranges, and response frequencies, were performed 
on the anonymous survey responses utilizing Microsoft Excel software. Data were analyzed and 
presented in the context of comparison between participants who pursued genetic testing for their 
children and participants who did not pursue genetic testing for their children, who will be 
designated as +Genetic Testing and -Genetic Testing, respectively, for sake of ease for the 
remainder of this document. Incomplete survey responses were included in survey analysis when 
participants answered the specific question and there was no reason to question the information 
that they provided. 
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3.3 RESULTS 
3.3.1  Demographic Information 
The survey was distributed to 63 households that had one or more children affected with 
HCM and 13 provided partial or full responses, yielding a 21% response rate. Of the 13 responses, 
11 respondents finished the survey to completion. Respondents, who were the parents or guardians 
of the child, were asked the age, sex, race/ethnicity, and health insurance of their affected child. 
The mean age of affected children in this population was 10.1 years with a range of 3 years to 20 
years. The majority of respondents, 81.8%, had male children affected with HCM. All respondents 
indicated that their child had health insurance; 60% had private insurance, while 40% had medical 
assistance. One individual did not indicate whether or not their child had insurance nor what type 
(Table 1). 
Additional information was collected about the characteristics of families who responded 
to the survey. The majority of survey respondents’ families live in a rural community (54.5%). 
Also, the majority of survey respondents indicated that one parent works in the healthcare or 
medical field (63.6%). Of note, no respondents indicated that their child affected with HCM was 
adopted and/or in foster care (Table 7, Appendix E). 
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Table 1 Demographic Information  
* Hispanic, **Mix 
Variable +Genetic Testing -Genetic Testing Total 
Age (years)  
Mean±SD 8.8±5.9 11.3±7.0 10.1±6.3 
Range 4.0-20.0 3.0-16.0 3.0-20.0 
Sex  
Female 16.7% (1) 20.0% (1) 18.2% (2) 
Male 83.3% (5) 80.0% (4) 81.8% (9) 
Race/Ethnicity  
Caucasian 83.3% (5) 40.0% (2) 63.6% (7) 
African American 0% (0) 40.0% (2) 18.2% (2) 
Other 16.7% (1)* 20.0% (1)** 18.2% (2) 
Health Insurance   
Private Insurance 60.0% (3) 60.0% (3) 60.0% (6) 
Medical Assistance 40.0% (2) 40.0% (2) 40.0% (4) 
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3.3.2  Genetic Evaluation 
 
Figure 1 Genetic Testing Status 
Respondents were asked questions about whether or not their child had received genetic 
testing and 58% of respondents said their child had received genetic testing for HCM, while 42% 
said their child had not (Figure 1). The parents who indicated that their child had received genetic 
testing were asked questions distinct from those who indicated that their child had not received 
genetic testing. However, both groups were asked about the healthcare professional(s) who follow 
their child for the HCM diagnosis, which is summarized in Table 2. 
Table 2 Healthcare Providers for HCM 
 
 +Genetic Testing -Genetic Testing Total 
Who does your child see for 
hypertrophic cardiomyopathy? 
 
Cardiologist 100% (6) 100% (4) 100% (10) 
Geneticist 33.3% (2) 0% (0) 20.0% (2) 
Genetic Counselor 16.7% (1) 25% (1) 20.0% (2) 
Primary Care Physician 0% (0) 25% (1) 10% (1) 
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3.3.2.1 +Genetic Testing 
Families who indicated that their child had received genetic testing were asked if they had 
requested genetic testing or whether their healthcare provider recommended it. 100% of 
respondents said that their healthcare provider recommended the genetic test. Of the seven 
participants whose child had genetic testing, one indicated their child had a positive result, one 
indicated a negative result, one indicated a variant of uncertain significance, and four indicated 
that they are not sure of the result. It is not possible to discern from the survey results whether 
these four individuals were not able to understand their child’s genetic test result, or if their child’s 
testing results were not yet available. However, one of these four participants indicated in the 
survey that their child’s testing was still in progress, which is why that participant indicated “not 
sure” as a response. 
Participants who pursued genetic testing for their child were also asked open-ended 
questions about their experience with genetic testing, specifically regarding what ways genetic 
testing was valuable and not valuable (Table 3).  
Table 3 Value of Genetic Testing 
In what ways, if any, 
was your child’s 
genetic testing…? 
Valuable Not Valuable 
Parent 1 It ruled out several other 
known causes of related health 
issues 
It did not provide an answer to 
the cause of her issues 
Parent 2 To prove he had the same 
mutation as his grandmother 
None 
Parent 3 Understanding the risk of 
passing the mutated genes to 
offspring 
Not knowing if the mutated 
genes was the cause of HCM 
Parent 4 We found that he’s a carrier of 
CF that is all.  Otherwise, it 
was not helpful. 
We never did find the 
mutation, so we still have no 
cause. 
Parent 5 To know for sure he had the 
heart condition 
* 
*Parent 5 did not respond to this item. 
 
 41 
3.3.2.2 -Genetic Testing 
Whenever participants indicated that they had not pursued genetic testing for their child, 
they were next asked if they were interested in genetic testing. Additionally, they were asked to 
specify the main reasons for not pursuing genetic testing at this time (Figures 2 and 3). Based on 
the responses from both questions, 4 participants out 5 participants who had not pursued genetic 
testing expressed interest in doing so (80%, standard error = 0.179). (Of note, one respondent 
indicated both interest and no interest in pursuing genetic testing.) 
 
 
Figure 2 Interest in Genetic Testing 
0
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2
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3
3.5
Yes No Not sure
Are you interested in pursuing genetic testing for your child for hypertrophic
cardiomyopathy in the future?
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Figure 3 Reasons for Not Pursuing Testing 
 
Lastly, participants were asked if there was anything they would like to know about genetic 
testing before making their decision about pursuing it for their child. One participant responded, 
and asked, “Will they test my other children?” 
3.3.3  Diagnosis and Family History 
Another section of the survey contained questions regarding the events surrounding the 
child’s diagnosis of HCM, including at what age and how they were diagnosed (Table 4). For the 
participants who indicated “other,” the reasons cited included “diagnosed at birth with difficulty 
breathing” and “discovered by chance during a visit to ER for upper respiratory infection (via chest 
x-ray)”. The majority of +Genetic Testing as well as total children diagnosed with HCM were 
0
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child’s healthcare 
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more pressing 
medical issues)
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diagnosed most frequently through the detection of a murmur or heart problem upon routine check-
up (71.4% and 58.3%, respectively). However, for the -Genetic Testing group, the majority had a 
family history of HCM, which prompted a cardiac evaluation (60%).  
 
Table 4 Diagnosis Information 
*Participants could select multiple responses and therefore, the total does not add up to 100%. 
 
Table 5 Sibship of Affected Child 
 
Variable +Genetic Testing -Genetic 
Testing 
Total 
How old was your child when he/she was 
diagnosed? 
 
Mean±SD (years) 8.0±6.7 2.2±3.9 5.4±6.1 
Range (years) Birth – 15 Birth – 8 Birth – 15 
Why was your child originally referred to 
be evaluated for hypertrophic 
cardiomyopathy?* 
 
A murmur or heart problem was detected 
upon routine checkup 
71.4 % (5) 40.0% (2) 58.3% (7) 
Family history – cardiac (heart) evaluation 
was done 
0.0% (0) 60.0% (3) 25.0% (3) 
Child was having symptoms (dizziness, 
chest pain, fainting, palpitations, shortness 
of breath, other) 
14.3% (1) 20.0% (1) 16.7% (2) 
Other 28.6% (2) 0.0% (0) 16.7% (2) 
 +Genetic Testing -Genetic Testing Total 
Do you have other 
children? 
 
Yes  85.7% (6) 40.0% (2)  66.7% (8) 
     Affected 0.0% (0) 100.0% (2)            25.0% (2) 
     Unaffected 100.0% (6) 0.0% (0)            75.0% (6) 
No, but I am planning on 
having more children 
14.3% (1) 20.0% (1)  16.7% (2) 
No, and I am not planning 
on having more children 
0.0% (0) 40.0% (2)  16.7% (2) 
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Participants were also asked if they had any other children besides their child affected with 
HCM (Table 5). Most of the +Genetic Testing participants have other children (85.7%), while the 
majority of -Genetic Testing participants do not (60%). As shown in Table 5, for the respondents 
who do have children, 25% of the total individuals have a second child who is affected. 
Additional questions were asked of participants regarding family history. Participants who 
did indicate a family history specified affected family members, which included grandparents, 
aunts/uncles, and cousins (Figure 4). Participants who indicated their child had a family history of 
HCM were also asked how many people, other than their affected child, were diagnosed with 
HCM. One participant in the +Genetic Testing group said that one other family member was 
affected, while another participant said two other family members are affected. The three 
participants in the -Genetic Testing group with a family history responded that they had two, five, 
and seven or eight other family members diagnosed with HCM. 
Figure 5 indicates the frequency of responses regarding whether or not individuals think 
that they are at risk for HCM based on their child’s diagnosis. Another way perceived risk was 
assessed was by asking whether or not participants have been screened for HCM (Table 6). Most 
participants in both groups indicated that they have been screened in some way at this time 
(66.7%). Of note, 100% of participants said that they had been counseled regarding the way that 
HCM can be passed down through a family. 
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Figure 4 Family History of HCM 
 
 
 
Figure 5 Perceived Risk of HCM 
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Table 6 Cardiac Screening 
 +Genetic Testing -Genetic Testing Total 
Have you been screened for 
hypertrophic cardiomyopathy?  
 
Yes, I saw a cardiologist 71.4%  (5) 60.0% (3) 66.7% (8) 
Yes, I had an echocardiogram 71.4%  (5) 40.0% (2) 58.3% (7) 
Yes, I had an electrocardiogram 57.1% (4) 40.0% (2) 50.0% (6) 
Yes, I had a Holter monitor 42.9% (3) 40.0% (2) 41.7% (5) 
Yes, I had genetic testing 28.6% (2) 0.0% (0) 16.7% (2) 
No, I have not been screened at 
this time 
28.6% (2) 40.0% (2) 33.3% (4) 
 
3.3.4  Risks and Benefits 
Respondents (N=11) were asked about the main risks and benefits of genetic testing. 
Benefits cited by respondents included identifying family members at risk to develop HCM (N=9, 
81.8%); relief, from gaining knowledge and potentially having a definitive answer (N=9, 81.8%); 
contributing to genetic information and/or research (N=8, 72.7%); providing a more complete 
understanding of their child’s HCM diagnosis (N=8, 72.7%); and helping to direct care for their 
child for HCM (N=5, 45.5%). 
Risks of genetic testing that respondents cited were financial cost (N=8, 72.7%); possible 
future discrimination by employers and/or insurance (N=3, 27.3%); time-consuming, lengthy 
process, (N=3, 27.3%); incidental findings (N=3, 27.3%); and anxiety and distress, from waiting 
for the result and/or its implications for their child and family (N=3, 27.3%).  
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3.3.5  Attitudes and Beliefs 
All respondents were asked to complete a Likert-scale portion of the survey, which aimed 
to elicit family attitudes towards, experience with, and knowledge regarding genetic testing. The 
wording was dependent on whether or not the participant’s child had genetic testing (Table 8, 
Appendix E) or did not have genetic testing (Table 9, Appendix E). The statements posed to 
participants were similar in construction in order to facilitate comparison between the two groups. 
The purpose of the statements posed in this section of the survey was to gather additional 
information regarding factors that either motivated or deterred families from pursing genetic 
testing. For example, both groups were asked whether or not they pursued (+Genetic Testing) or 
would pursue (-Genetic Testing) genetic testing to learn more about the risk of HCM for their other 
children (e.g., their affected child’s siblings) (Figure 6). Additional factors that were elicited to 
determine whether or not they had/would have had an impact on genetic testing included 
advisement by healthcare professionals, requests from family members, motivation to gain 
information on personal (parental) HCM risk, motivation to gain information on HCM risk for 
other family members, health insurance coverage, accessibility, and possible negative impact. 
Lastly, this section contained one item that assessed awareness and understanding by 
stating the general basis of Genetic Information Non-Discrimination Act, or GINA, and the 
protections it provides for patients who undergo genetic predisposition testing (Figure 7). This 
item was not only elicited to determine if awareness appears to impact the decision whether or not 
individuals pursued genetic testing, but also assessed if participants were informed of this law.  
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Figure 6 Impact of Siblings’ Risks on Affected Child’s Genetic Testing Status 
 
 
Figure 7 Perception of GINA 
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The statements in the final section of the survey aimed to elicit perceptions on the 
information that can be gained from genetic testing (Tables 10 and 11, Appendix E). Similar to the 
previous section, the participants had different wording based on whether or not their child had 
genetic testing, but the items for both groups were worded in a similar manner. The primary 
difference between the way that items were framed between the +Genetic Testing and -Genetic 
Testing groups is the fact that +Genetic Testing participants were posed statements based on the 
actual impact that genetic testing had on their family, while the statements for the -Genetic Testing 
group were framed in a manner in which they were asked to cite their perceptions regarding genetic 
testing.  
Within this section, some statements focused on psychosocial factors, including whether 
genetic testing caused/would cause anxiety and distress (Figure 8), relief, and/or concern regarding 
health insurance coverage. Additionally, other items in this section were targeted to gain more 
information regarding the impact of genetic testing on behavior changes, including whether or not 
genetic testing encouraged/would encourage the family to take action towards a healthier lifestyle 
and whether or not genetic testing helped/would help the family make better healthcare decisions.  
The final statement in this section to which participants responded elicited attitudes 
regarding the helpfulness of genetic testing (Figure 9), in the context that all of the affected 
children already had clinical diagnoses of HCM. This item elicited the comparison between groups 
to determine whether or not the +Genetic Testing group found genetic testing helpful, and if the -
Genetic Testing ground perceived genetic test results to be informative. Like the aforementioned 
GINA item in the previous section, this statement also elicits an education piece (e.g., whether or 
not participants were educated on and/or are aware of the benefits of genetic testing in the 
information it can offer a patient and their family). 
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Figure 8 Impact of Anxiety & Distress on Genetic Testing Status 
 
 
Figure 9 Perception of the Usefulness of Genetic Testing 
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3.4 DISCUSSION 
3.4.1  Demographic Information 
Although the number of respondents was small and statistical analysis could not be 
conducted, the -Genetic Testing group was associated with more racial and ethnic minorities than 
the +Genetic Testing group. Previous studies have identified barriers to genetic testing that are 
associated with racial and ethnic disparities (Suther and Kiros, 2009; Forman and Hall, 2009). One 
study determined that differences in knowledge regarding genetic testing, levels of mistrust, and 
health insurance coverage can exist in different races and ethnic groups (Suther and Kiros, 2009). 
Both groups who pursued and did not pursue genetic testing had equal frequencies of individuals 
who had private insurance and Medicaid. Therefore, this reduces insurance as a potential barrier, 
although individuals did cite insurance denial and cost as reasons why they did not pursue genetic 
testing in this study. Insurance companies have different requirements regarding genetic test 
coverage. For example, many insurance companies mandate pre-test genetic counseling. If this 
does not occur, then there is the possibility that the genetic test will get denied (Stenehjem et al., 
2018). 
3.4.2  Genetic Evaluation 
A study by Khouzam et al. (2015) found that seeing a genetic professional was considered 
a predictor of whether or not HCM patients have had genetic testing. However, in the current study, 
individuals from both groups had seen genetic professionals.  
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3.4.2.1 +Genetic Testing 
Similar to previous research, the current study found that a family’s healthcare provider 
could be a motivator for genetic testing (Anderson et al., 2012; Delikurt et al., 2014). Every 
individual in the +Genetic Testing group said that their healthcare provider recommended genetic 
testing.  
Statements made by respondents in this section of the survey illustrated important concerns 
regarding certain risks and misconceptions about genetic testing. For example, one respondent 
designated as Parent 5, said that genetic testing was valuable because it confirmed he had a heart 
condition. However, it is important to emphasize to families even in the event of negative genetic 
testing, a child who is clinically diagnosed with HCM still has that diagnosis regardless of the 
genetic test result. Multiple parents indicated that genetic testing was not valuable because it did 
not identify an answer for their child, since it did not identify a pathogenic variant associated with 
HCM. Lastly, four out of six parents indicated that they are not sure of their child’s genetic test 
result. As previously mentioned, it was unclear whether this response was due to the fact that the 
results have not yet been disclosed or a lack of understanding of what their child’s genetic test 
result means. These statements and data indicate that even families who have pursued genetic 
testing may have a misunderstanding regarding the information genetic testing can provide and its 
result. 
3.4.2.2 -Genetic Testing 
One of the primary aims of this study was to elicit barriers to genetic testing in this patient 
population. Interestingly, four out of five respondents who did not pursue genetic testing for their 
child indicated some type of interest in genetic testing; this may suggest that barriers to testing do 
exist for this population. The most commonly cited reason for not pursuing testing was that genetic 
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testing was denied by insurance, which is consistent with prior research (Vande Wydeven et al., 
2012; Anderson et al., 2012). Other reasons included cost, uncertainty of how to attain testing, and 
more pressing health concerns for their child. These concerns have been identified in previous 
research in multiple genetic counseling practice settings and across diverse populations (Vogel et 
al., 2018; Kutscher et al., 2017; Beene-Harris et al., 2007). The majority of these barriers are 
considered institutional barriers to access rather than individual barriers.  
3.4.3  Diagnosis and Family History 
One finding regarding the family history was that participants who had not pursued genetic 
testing reported a greater frequency of family history when compared to participants who pursued 
genetic testing. In previous studies, family history of conditions has been a predictor for 
individuals pursuing genetic testing; this has been established across different types of genetic 
counseling practice settings (Wessel et al., 2016; Khouzam et al., 2015). However, one study did 
cite that a barrier to genetic testing was the failure on the healthcare professional’s part in obtaining 
a detailed family history (Delikurt et al., 2014). This finding requires further investigation. For 
example, it would be useful to know whether these individuals had been offered genetic testing 
and whether their health care providers were aware of the HCM family history. These issues were 
not explored in this research study. Additionally, two individuals who had not pursued genetic 
testing for their child also said they had other children who were affected with HCM, while 
participants who had pursued genetic testing for their children did not have any other children who 
were affected. This provides further evidence that family history was possibly not related with 
pursuing genetic testing in this study. 
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3.4.4  Risks and Benefits 
The risks and benefits of genetic testing were elicited from all respondents. The data 
collected were consistent with other perceived risks and benefits that have been elucidated in other 
studies. For example, the most frequently cited perceived benefit of genetic testing was identifying 
family members at risk to develop HCM. The second most frequently cited perceived benefit was 
providing a more complete understanding of a child’s HCM diagnosis, which is congruent with a 
previous qualitative study that found individuals were enthusiastic about genetic testing because it 
can potentially reduce diagnostic uncertainties (McGowan et al., 2013). 
In terms of risks that were found by this study, financial cost was the most frequently noted 
perceived risk. As previously mentioned, insurance coverage and cost were identified as major 
reasons that the -Genetic Testing respondents did not pursue genetic testing; this risk remained 
consistent across both individuals who did and did not pursue genetic testing. An additional 
perceived risk included possible future discrimination by employers and/or insurance, which was 
cited by three individuals. This indicates that these individuals may be unaware of or 
misunderstand the Genetic Information Non-Discrimination Act, or GINA, which protects 
individuals who pursue genetic testing from discrimination from employers and health insurance 
based on their result. This remained consistent throughout the survey and will be discussed further 
in the next section. 
3.4.5  Attitudes and Beliefs 
An apparent motivator for pursuing genetic testing for this specific population is to learn 
about risk for other children. All respondents who had pursued genetic testing for their child 
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strongly agreed that they pursued it to learn about the risks for their other children. However, only 
40% in the group that did not pursue genetic testing said that it was a motivator for them. 
Responses regarding other factors that could potentially be motivating or deterring to pursing 
genetic testing that were assessed were overall comparable between both groups.  
A number of respondents cited that genetic testing resulted in anxiety and distress. Four 
respondents (66.7%) either strongly or somewhat agreed with the statement that the information 
gained from their child having a genetic test for HCM caused a lot of anxiety and distress. 
Furthermore, three respondents (50%) strongly agreed with the statement that the information 
gained from their child having a genetic test for HCM made them concerned about their child’s, 
their own, and/or other family members’ future health insurance coverage. For participants who 
did not pursue genetic testing, none agreed with the statement that genetic testing would cause 
anxiety and distress. Thus, anxiety and distress seem like unlikely barriers for those who did not 
pursue genetic testing; it appears that genetic testing may have caused anxiety for families who 
pursued it. However, information regarding the participants’ anxiety levels before testing was not 
assessed.  
Another interesting finding within the attitudes and beliefs section of the study was all 
respondents who had attained genetic testing for their child either agreed or were neutral regarding 
the statement that their child’s genetic testing was not helpful because their child was already 
diagnosed with HCM. For individuals who did not pursue genetic testing, 80% of participants 
agreed with this statement. This trend is consistent with prior cardiogenetic research which has 
found that families encounter difficulty understanding the results of genetic testing. Furthermore, 
a study conducted by Ormondroyd et al. (2013) indicates that families who do not have an 
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understanding of the results of genetic testing are less likely to share the genetic test result with at-
risk family members than families who do understand the result.  
In regard to discrimination, it is possible that respondents are not aware or do not 
understand GINA. Only 20% of individuals who had pursued genetic testing for their child and 
40% who had not pursued genetic testing for their child agreed with the statement, “GINA (the 
Genetic Information Non-discrimination Act) is a law that was passed in 2008 that makes sure 
health insurance companies will not deny coverage and employers cannot make hiring/firing 
decisions based on genetic testing results. GINA will protect my child from future discrimination 
and unlawful termination of employment and ensure their access to health insurance.” There are a 
couple of potential explanations for these results. One possibility is a lack of awareness or 
misunderstanding of GINA, which would be consistent with a prior study that showed the majority 
of patients in their population were not aware of this law (Cragun et al., 2019). Another possible 
explanation is that respondents are aware and educated on GINA but interpreted the statement 
from the perspective of the permanence of GINA (e.g., GINA may not exist in the future to protect 
my child from discrimination). Like the anxiety and distress measure, it does not appear that a lack 
of familiarity with GINA and/or uncertainty of its permanence was a barrier to genetic testing in 
this population. However, it does appear that GINA and its relationship to discrimination should 
be addressed in both pre- and post-counseling sessions, to aid in decision-making as well as to 
help parents understand the impact of genetic testing results on their child’s future.   
3.4.6  Study Limitations 
There are several limitations to this study. The main limitation of this study was the small 
sample size of respondents to the survey. Inferential statistics were not appropriate given the small 
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sample size. Thus, it could not be determined whether or not there were any statistically significant 
trends within this sample, or statistical differences between the +Genetic Testing and -Genetic 
Testing groups for any of the variables that were assessed. 
Another limitation of this study is that its results are most likely not generalizable to other 
populations, specifically for other pediatric heart conditions. When determining the scope of this 
study, there was an opportunity to survey a larger patient population of pediatric patients with 
cardiac conditions. However, many inherited conditions are approached differently by healthcare 
providers. Thus, different barriers may exist for specific heart conditions. For example, cardiac 
conditions like Long QT syndrome, which are more frequently genetic, are intuitively more likely 
to be offered genetic testing. The inclusion of multiple inherited cardiac conditions would have 
possibly allowed for a larger population and more informative comparisons, but the data may have 
been different depending on the condition and thus inappropriate to combine. The scope of the 
study was focused on HCM specifically since it is considered the most common inherited cardiac 
condition, thus allowing for the largest possible sample while looking at one condition. 
A third limitation of this survey is the fact that timing of the genetic testing discussion by 
a healthcare provider with patients’ families was not explicitly elicited. If a healthcare provider 
brings up genetic testing at the first visit, which is typically the same time as the initial diagnosis 
of HCM for the patient, this potentially may that have been the reason that it was not pursued (e.g., 
family had too much to think about). Furthermore, perhaps it was not considered because the 
cardiologist brought it up at that first visit with minimal information and/or informed consent 
because there was too much to review. Conversely, if there is a follow-up visit with more time and 
space to discuss genetic testing, parents may be more inclined to pursue at that time. This piece of 
information is a potential barrier to genetic testing and would be useful to incorporate to help 
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further determine why some families do or do not pursue genetic testing.  Future studies focused 
on this topic should include analysis of this timing factor, and it may even be beneficial to survey 
healthcare providers to determine when they typically have this conversation and why.  
Lastly, this study is also limited by its use of an anonymous survey. Thus, the data cannot 
be linked to individuals’ medical record review. For this reason, researchers relied on self-reported 
data, and the information provided by participants was unable to be confirmed by a medical record 
review. 
3.4.7  Future Directions 
This research study offers preliminary evidence to indicate that individuals with children 
with HCM may not have complete understanding and awareness regarding genetic testing options 
for their child. A reasonable direction for future research would include studying the impact of the 
implementation of a cardiovascular genetic clinic on patient access, awareness, and understanding 
of genetic testing, as compared to this patient population. Additionally, given the research findings 
that both parents who did and did not pursue genetic testing do not have a complete understanding 
of GINA, it is possible that this law is not routinely explained to families. There is limited research 
on this topic in regard to patient and physician awareness; only a handful of studies were found 
that explored this topic (Allain et al., 2012; Cragun et al., 2019; Dorsey et al., 2013; Laedtke et al., 
2012; Parkman et al., 2015). It is important that the understanding of both healthcare providers 
who offer genetic testing as well as families who are pursuing genetic testing be further explored. 
Thus, a survey of cardiovascular healthcare providers, including cardiologists, genetic counselors, 
nurse practitioners, etc., would be useful to determine what information they communicate to their 
patients regarding genetic testing. 
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Another direction for future research presented by this study is to look at insurance more 
closely in its role as a potential barrier to genetic testing for pediatric patients with HCM. Insurance 
denial was the primary reason that families did not pursue genetic testing. However, participants 
who pursued and did not pursue genetic testing had equal frequencies of individuals who had 
private insurance and Medicaid. Additionally, several prior studies across genetic counseling 
practice settings have also elucidated insurance as a barrier to testing (Vande Wydeven et al., 2012; 
Kutscher et al., 2017; Spoonamore and Johnson, 2016). Given these findings, it may be useful to 
specifically analyze the types of private insurance and their policies on genetic testing, as well as 
compare the similarities and differences between families who had genetic testing approved and 
families who had genetic testing denied. This will gather more information on the specific reasons 
that insurance companies deny coverage of testing, so institutions can address these to reduce the 
chance of insurance denial of testing.  
As genetic testing becomes more widespread and attitudes about testing change, it is 
anticipated that the number of individuals who are offered genetic testing will increase. 
Additionally, more genetic counselors may practice in cardiovascular settings, and insurance 
companies may more readily cover testing as it becomes a standard of practice. Thus, it may be 
inappropriate for future studies to build on this research; rather, it may be more beneficial to use it 
as a comparison if the barriers that this study elucidated are no longer issues, and other barriers 
arise. 
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3.5 CONCLUSION 
This study offers preliminary data regarding possible barriers to genetic testing in families 
of pediatric hypertrophic cardiomyopathy patients. It provides directions for future research to 
explore in larger patient populations and additionally helps clarify perceived risks and benefits of 
families who have pursued genetic testing for HCM.  
The first aim of the study was to survey the parents and/or guardians of pediatric patients 
with HCM that have been seen by pediatric cardiology at UPMC Children’s Hospital of Pittsburgh 
and received a clinical diagnosis of HCM. The survey had a 21% response rate, and the sample 
was about equally represented by parents who had pursued and who had not pursued genetic testing 
for their child. 
The second specific aim of this project was to analyze the survey data to elicit the reasons 
parents and/or guardians do not pursue genetic testing for their children. Based on the responses 
that questioned the interest in genetic testing of respondents who had not pursued genetic testing 
for their child, it was determined that 80% were interested in moving forward with testing. The 
primary reasons testing was not pursued as well as perceived risks of genetic testing included 
insurance denial of testing, financial concerns, and cost of testing. Additional reasons identified 
included uncertainty regarding how to pursue genetic testing and other priorities with respect to 
their child’s health and family. Apparent facilitators to genetic testing in this study included 
concern regarding HCM risk for other children and healthcare providers recommending genetic 
testing, both which 100% of participants who had pursued genetic testing cited. 
The final aim of this project was to identify barriers so that strategies to reduce these 
barriers can be incorporated into the newly formed Cardiovascular Genetics Clinic at UPMC 
Children’s Hospital of Pittsburgh. For example, the provision of genetic counseling services for 
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each cardiology patient would possibly reduce several of the identified barriers. Genetic 
counseling can provide the time and resources to obtain a detailed family history, thoroughly 
educate a family on the risks and benefits to genetic testing, increase the likelihood to obtain 
insurance coverage, and explore alternative finance options. Additionally, this research can allow 
clinicians to better target certain areas of discussion regarding genetic testing. One finding of this 
study is that participants who had and had not pursued genetic testing for their child lacked 
awareness and knowledge regarding GINA. Based on this data, an impactful adaptation to the 
typical genetic testing pre-test and post-test counseling would include an in-depth discussion and 
resources to explain GINA.   
While the generalizability of these results to other populations is limited, this research 
provides preliminary data for the necessity of clinicians to educate and provide genetic testing 
options for their patients. Additional studies may be warranted in order to further investigate the 
differences between groups of families who have and have not pursued genetic testing, to 
determine whether or not they approach statistical significance for any of the variables that have 
been assessed in this study. As genetic testing and genetic counseling continues to evolve and 
become more widespread, it is possible that these barriers will decrease, and knowledge, 
awareness, and coverage of genetic testing will improve. 
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4.0 PUBLIC HEALTH AND GENETIC COUNSELING SIGNIFICANCE 
4.1 RESEARCH SIGNIFICANCE TO PUBLIC HEALTH 
Understanding the barriers to genetic services for pediatric HCM patients and their families 
is the first step to implementing a plan to alleviate these barriers and improve access for patients 
at UPMC Children’s Hospital of Pittsburgh. One of the core functions of public health is assurance, 
which is defined as, “promoting and protecting public interests through programs, events, 
campaigns, regulations and other strategies, and making sure that necessary services are provided 
to reach agreed upon goals” (Institute of Medicine, 1988). The purpose of this study was to identify 
perceptions of genetic testing and possible barriers to genetic testing for families of pediatric HCM 
patients at UPMC Children’s Hospital of Pittsburgh. Thus, identifying these barriers promotes 
assurance that genetic counseling and genetic testing are being offered consistently to pediatric 
HCM patients. Based on the collected data, pediatric patients typically meet with a cardiologist 
only, who is responsible for discussing and coordinating genetic testing. A genetic counselor is 
not usually available to meet with every HCM patient. Based on this study, some families did have 
genetic counseling and genetic testing while other families did not. While it is uncertain based on 
this data whether or not all families were offered genetic services, one concern is that some families 
are not provided genetic services. In order to mitigate this concern, a reasonable outcome would 
be to promote more consistency among all cardiology healthcare providers to ensure that their 
patients are offered genetic testing and provided insurance authorization by their provider, as well 
as adequate education to ensure sufficient/appropriate understanding of the risks, benefits, and 
information that genetic testing provides. 
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One of the essential services within the core function of assurance is to, “evaluate 
effectiveness, accessibility, and quality of personal and population-based health services” 
(Institute of Medicine, 1988). This study evaluated the barriers to genetic services and found that 
80% of participants who did not pursue genetic testing for their child were interested in obtaining 
genetic testing for their child. This research was important because it identified actionable barriers 
including insurance coverage, cost, uncertainty of how to attain testing, and more pressing health 
concerns for their child. Future research may explore a possible lack of accessibility to genetic 
services for some families within this population based on these results. Additionally, knowledge 
of these barriers can promote further studies and potentially the implementation of strategies to 
improve the financial coverage for genetic testing and streamline the genetic testing process for 
pediatric HCM patients. 
4.2 RESEARCH SIGNIFICANCE TO GENETIC COUNSELING 
Genetic counselors play a significant role in educating families of pediatric patients with 
HCM and facilitating the genetic testing process. In addition to the data collected regarding the 
barriers to genetic testing in this patient population, a deficit in patient understanding regarding 
the utility and issues associated with genetic testing is suggested by this research. Therefore, there 
is a need to further educate patients regarding what genetic testing is and the information that it 
provides. A Genetic Counseling Practice-Based Competency as established by ACGC states that 
genetic counselors, “effectively educate clients about a wide range of genetics and genomics 
information based on their needs, their characteristics and the circumstances of the encounter” 
(Doyle et al., 2016).  One of the study findings indicates that participants, specifically those who 
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had already pursued testing for their child, felt that the genetic test was uninformative because 
their child was already diagnosed with HCM. Additionally, the survey data indicated the possible 
need for additional education in certain areas such as GINA. Thus, these issues should be allotted 
more time for discussion. Additionally, distribution of educational resources focusing on the 
information that genetic testing provides as well as legal significance associated with the testing 
should be considered to reinforce parents’ understanding regarding the implications of this testing 
for their child and family. Future research can continue to delineate specifics regarding the 
appropriate timing for this information, including the timing of the discussion regarding genetic 
testing and distribution of educational resources (e.g., when the child is diagnosed versus at a 
follow-up appointment when the family has had some time to process the diagnosis). 
Ensuring that pediatric HCM patients and their families have access to genetic testing, as 
well as the understanding to make an informed decision regarding genetic testing and an 
appreciation for what a genetic result will mean for the patient’s family demonstrates the 
importance of this research study to the genetic counseling and public health fields. This research 
highlights a need for genetic counselors in a cardiovascular clinic. Additionally, this study 
demonstrates a need to offer genetic testing as a standard of clinical care for individuals with HCM. 
While it is ultimately the patient’s decision regarding whether or not they pursue genetic testing, 
this research suggests that many families may depend on their healthcare provider, insurance 
coverage, and additional factors that were not assessed within the scope of this study. Overall, this 
research has the potential to impact not only clinical practice in the Cardiovascular Genetics Clinic 
at UPMC Children’s Hospital of Pittsburgh but could ultimately impact the approach to patient 
care in other cardiovascular genetics clinics. 
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APPENDIX E SUPPLEMENTAL DATA 
Table 7 Supplemental Demographic Data 
Variable +Genetic 
Testing 
-Genetic 
Testing 
Total 
What is your family’s home community?  
Urban 16.7% (1) 0% (0) 9.1% (1) 
Suburban 33.3% (2) 40.0% (2) 36.4% (4) 
Rural 50.0% (3) 60.0% (3) 54.5% (6) 
How far away do you live from UPMC 
Children’s Hospital of Pittsburgh? 
 
30 minutes or less 16.7% (1) 0% (0) 9.1% (1) 
Between 30 minutes and 1 hour 33.3% (2) 40.0% (2) 36.4% (4) 
Between 1 hour and 2 hours 16.7% (1) 20.0% (1) 18.2% (2) 
Between 2 hours and 3 hours 16.7% (1) 20.0% (1) 18.2% (2) 
3 hours or more 16.7% (1) 20.0% (1) 18.2% (2) 
What is the highest level of education 
obtained by someone in your household? 
   
High school graduate (high school diploma 
or equivalent including GED) 
16.7% (1) 0% (0) 9.1% (1) 
Some college but no degree 16.7% (1) 40.0% (2) 27.3% (3) 
Associate degree in college (2-year) 16.7% (1) 0% (0) 9.1% (1) 
Bachelor’s degree in college (4-year) 16.7% (1) 40.0% (2) 27.3% (3) 
Master’s degree 16.7% (1) 20.0% (1) 18.2% (2) 
Professional degree (JD, MD) 16.7% (1) 0% (0) 9.1% (1) 
Does someone in your household work in the 
healthcare or medical field? 
   
Yes 66.7% (4) 60.0% (3) 63.6% (7) 
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No 33.3% (2) 40.0% (2) 36.4% (4) 
How are you related to your child with 
HCM? 
   
Mother 83.3% (5) 80.0% (4) 81.8% (9) 
Father 16.7% (1) 0% (0) 9.1% (1) 
Other* 0% (0) 20.0% (1) 9.1% (1) 
*Grandmother 
Table 8 Attitudes of + Genetic Testing Respondents 
 Strongly 
agree 
Somewhat 
agree 
Neither 
agree nor 
disagree 
Somewhat 
disagree 
Strongly 
disagree 
N/A 
I pursued genetic testing for 
my child because my 
healthcare provider advised me 
to. 
5 (83.3%) 1 (16.7%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Requests from my family 
members encouraged me to 
pursue genetic testing for my 
child. 
1 (16.7%) 1 (16.7%) 1 (16.7%) 0 (0%) 2 
(33.3%) 
1 (16.7%) 
I pursued genetic testing for 
my child to learn about the 
risks for myself. 
4 (66.7%) 1 (16.7%) 0 (0%) 0 (0%) 0 (0%) 1 (16.7%) 
I pursued genetic testing for 
my child to learn about the 
risks for my other children (if 
applicable). 
6 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
I pursued genetic testing for 
my child to learn about the 
risks for my other family 
members. 
4 (66.7%) 2 (33.3%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Health insurance coverage was 
a factor in my child getting 
genetic testing for hypertrophic 
cardiomyopathy. 
3 (50.0%) 1 (16.7%) 1 (16.7%) 0 (0%) 1 
(16.7%) 
0 (0%) 
Genetic testing was accessible 
to my child and my family. 
3 (50.0%) 2 (33.3%) 0 (0%) 0 (0%) 1 
(16.7%) 
0 (0%) 
I was hesitant to pursue genetic 
testing for my child because of 
the possible negative impact on 
myself and other family 
members. 
0 (0%) 1 (16.7%) 0 (0%) 1 (16.7%) 4 
(66.7%) 
0 (0%) 
GINA (the Genetic Information 
Non-discrimination Act) is a 
law that was passed in 2008 that 
makes sure health insurance 
companies will not deny 
coverage and employers cannot 
1 (20.0%) 0 (0%) 3 (60.0%) 0 (0%) 1 
(20.0%) 
0 (0%) 
Table 7 Continued 
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make hiring/firing decisions 
based on genetic testing results. 
GINA will protect my child 
from future discrimination and 
unlawful termination of 
employment and ensure their 
access to health insurance. 
 
Table 9 Attitides of -Genetic Testing Respondents 
 Strongly 
agree 
Somewhat 
agree 
Neither 
agree nor 
disagree 
Somewhat 
disagree 
Strongly 
disagree 
N/A 
I would pursue genetic testing for 
my child if my healthcare 
professional advised me to. 
1 (20%) 2 (40%) 2 (40%) 0 (0%) 0 (0%) 0 
(0%) 
Requests from my family members 
would make me more likely to 
pursue genetic testing for my child. 
0 (0%) 3 (60%) 2 (40%) 0 (0%) 0 (0%) 0 
(0%) 
I would pursue genetic testing for 
my child to learn about the risks 
for myself. 
0 (0%) 2 (40%) 1 (20%) 1 (20%) 0 (0%) 1 
(20%) 
I would pursue genetic testing for 
my child to learn about the risks 
for my other children (if 
applicable). 
2 (40%) 0 (0%) 1 (20%) 0 (0%) 0 (0%) 2 
(40%) 
I would pursue genetic testing for 
my child to learn about the risks 
for my other family members. 
1 (20%) 2 (40%) 1 (20%) 1 (20%) 0 (0%) 0 
(0%) 
Health insurance coverage would 
be a factor in my child getting 
genetic testing for hypertrophic 
cardiomyopathy. 
4 (80%) 0 (0%) 1 (20%) 0 (0%) 0 (0%) 0 
(0%) 
I believe my child would have 
access to genetic testing if I wanted 
to pursue it. 
1 (20%) 2 (40%) 1 (20%) 0 (0%) 1 (20%) 0 
(0%) 
I would prefer my child not get 
genetic testing because of the 
possible negative impact on myself 
and other family members. 
0 (0%) 0 (0%) 0 (0%) 1 (20%) 4 (80%) 0 
(0%) 
GINA (the Genetic Information 
Non-discrimination Act) is a law 
that was passed in 2008 that makes 
sure health insurance companies 
will not deny coverage and 
employers cannot make 
hiring/firing decisions based on 
genetic testing results. GINA will 
protect my child from future 
discrimination and unlawful 
termination of employment and 
ensure their access to health 
insurance. 
0 (0%) 2 (40%) 2 (40%) 0 (0%) 1 (20%) 0 
(0%) 
 
Table 8 Continued 
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Table 10 +Genetic Test Perception of Information 
 Strongly 
agree 
Somewhat 
agree 
Neither 
agree nor 
disagree 
Somewhat 
disagree 
Strongly 
disagree 
N/A 
Encouraged our family to take 
action towards a healthier lifestyle 
to prevent symptoms of 
hypertrophic cardiomyopathy 
2 
(33.3%) 
3 (50.0%) 1 (16.7%) 0 (0%) 0 (0%) 0 
(0%) 
Helped our family make better 
decisions regarding healthcare 
2 
(33.3%) 
3 (50.0%) 0 (0%) 1 (16.7%) 0 (0%) 0 
(0%) 
Made me concerned about my 
child’s, my own, and/or other 
family members’ future health 
insurance coverage 
3 
(50.0%) 
0 (0%) 1 (16.7%) 1 (16.7%) 1 (16.7%) 0 
(0%) 
Caused a lot of anxiety and distress 1 
(16.7%) 
3 (50.0%) 1 (16.7%) 0 (0%) 1 (16.7%) 0 
(0%) 
Caused relief to know my child’s 
genetic status 
3 
(50.0%) 
2 (33.3%) 0 (0%) 1 (16.7%) 0 (0%) 0 
(0%) 
Was not helpful because my child 
was already diagnosed with 
hypertrophic cardiomyopathy 
through a cardiac evaluation 
2 
(33.3%) 
1 (16.7%) 3 (50.0%) 0 (0%) 0 (0%) 0 
(0%) 
 
 
Table 11 -Genetic Test Perception of Information 
 Strongly 
agree 
Somewhat 
agree 
Neither 
agree nor 
disagree 
Somewhat 
disagree 
Strongly 
disagree 
N/A 
Encourage our family to take 
action towards a healthier 
lifestyle to prevent symptoms of 
hypertrophic cardiomyopathy 
3 
(60.0%) 
2 (40.0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Help our family make better 
decisions regarding healthcare 
3 
(60.0%) 
2 (40.0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Make me concerned about my 
child’s, my own, and/or other 
family members’ future health 
insurance coverage 
1 
(20.0%) 
3 (60.0%) 1 (20.0%) 0 (0%) 0 (0%) 0 (0%) 
Cause a lot of anxiety and distress 
 
0 (0%) 0 (0%) 3 (60.0%) 0 (0%) 1 (20.0%) 1 
(20.0%) 
Cause relief 1 
(20.0%) 
3 (60.0%) 1 (20.0%) 0 (0%) 0 (0%) 0 (0%) 
Is not helpful because my child 
can be diagnosed with 
hypertrophic cardiomyopathy 
through a cardiac evaluation 
1 
(20.0%) 
2 (40.0%) 2 (40.0%) 1 (20.0%) 0 (0%) 0 (0%) 
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